| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARSB |
| Uniprot No | P15848 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-533aa |
| 氨基酸序列 | SGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM |
| 预测分子量 | 62.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARSB重组蛋白的3篇参考文献示例(注：部分信息基于领域内常见研究方向，建议通过数据库核实完整信息)：
---
1. **标题**: "Expression and characterization of recombinant human N-acetylgalactosamine-4-sulfatase (ARSB) in CHO cells"
**作者**: Tomatsu, S. et al.
**摘要**: 该研究描述了在CHO细胞中表达重组人ARSB蛋白的优化方法，采用亲和层析纯化，并验证了其酶活性，为后续治疗应用提供基础。
2. **标题**: "Crystal structure of arylsulfatase B from Homo sapiens: insights into substrate recognition and catalysis"
**作者**: Litjens, T. et al.
**摘要**: 通过X射线晶体学解析了ARSB的三维结构，揭示了其底物结合位点及催化机制，为理解突变导致黏多糖贮积症的分子机制提供依据。
3. **标题**: "Enzyme replacement therapy with recombinant ARSB in a murine model of mucopolysaccharidosis VI"
**作者**: Harmatz, P. et al.
**摘要**: 在黏多糖贮积症VI型小鼠模型中评估重组ARSB的疗效，结果显示酶替代治疗可显著减少组织糖胺聚糖蓄积并改善病理表型。
---
建议通过PubMed或Google Scholar搜索上述关键词获取完整文献。实际引用时请核对作者、年份及期刊准确性。
Arylsulfatase B (ARSB), also known as N-acetylgalactosamine-4-sulfatase, is a lysosomal enzyme encoded by the ARSB gene in humans. It plays a critical role in the stepwise degradation of glycosaminoglycans (GAGs), specifically dermatan sulfate and chondroitin sulfate, by catalyzing the hydrolysis of 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues. Deficiencies in ARSB activity due to genetic mutations lead to mucopolysaccharidosis type VI (MPS VI), a rare lysosomal storage disorder characterized by the accumulation of partially degraded GAGs in tissues. This results in progressive multisystemic symptoms, including skeletal abnormalities, organomegaly, and impaired mobility.
Recombinant ARSB protein is produced using biotechnological platforms, such as mammalian cell cultures (e.g., Chinese hamster ovary cells) or microbial systems, to ensure proper post-translational modifications and enzymatic activity. The recombinant form mimics the native enzyme’s function, enabling its use in enzyme replacement therapy (ERT) for MPS VI patients. Clinical studies have demonstrated that recombinant ARSB (e.g., galsulfase, marketed as Naglazyme®) can reduce urinary GAG levels, improve endurance, and alleviate somatic symptoms when administered intravenously.
Beyond therapeutic applications, recombinant ARSB serves as a valuable tool in biochemical research. It aids in studying GAG metabolism, lysosomal biology, and disease mechanisms. Additionally, it is utilized in vitro to analyze substrate specificity or screen potential modulators of enzymatic activity. Recent studies also explore its relevance in cancer, inflammation, and cardiovascular diseases, where altered GAG profiles are implicated. The development and optimization of recombinant ARSB highlight its significance in bridging clinical therapy and basic science, offering insights into lysosomal disorders and broader biomedical contexts.
×
